专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP2957569A1 (ARGO)N-ANGIOTENSIN-(1-7) PEPTIDE AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISEASES 审中-公开
标题翻译：（ARGO）N - 血管紧张素 - （1-7）肽和药物组合物，疾病治疗
公开(公告)号：EP2957569A1
公开(公告)日：2015-12-23
申请号：EP13837467.3
申请日：2013-09-13
申请人： Universidade Federal De Minas Gerais - UFMG
发明人： SOUZA DOS SANTOS, Robson Augusto , FERNANDES VILAS BÔAS, Suéllen Kathiane , FÉLIX BRAGA, Janaina , JEAN GEORGES FREZARD, Frederic , DARIO SINISTERRA, Ruben , CALDEIRA SILVA, Neiva , QUEIROGA LAUTNER, Roberto , ARAÚJO FRAGA DA SILVA, Rodrigo
IPC分类号： C07K7/14 , A61K38/08 , A61P9/08
CPC分类号： C07K7/06 , A61K9/0019 , A61K9/0095 , A61K38/00 , C07K7/14 , C12N5/0653 , C12N5/0657 , C12N5/0693 , C12N2501/32
摘要： The present invention relates to the peptide (arg0) n-angiotensin-(1-7) [(arg0) n-Ang-(1-7)], where n is 1 to 10 (Xaa-Asp-Arg-Val-Tyr-Ile-His-Pro; SEQ ID NO:1 where Xaa represents 1 to 10 L-Arg residues), which is produced by inserting at least one arginine amino acid at the amino terminal position of Ang-(1-7), as well as pharmaceutical compositions containing this peptide and the use thereof for the treatment or prevention of diseases or disorders that are due or associated with reduced nitric oxide production. Non-limiting examples of these diseases or disorders are cardiopulmonary and liver diseases, vascular disorders, metabolic disorders, neural disorders, genito-urinary tract disorders, skeletal muscle disorders, kidney disorders, skin disorders, alopecia or tumors. The peptide is able to cause, for example, dilation of aortic and mesenteric vessels, reduction of mean arterial blood pressure, decrease of body weight gain, blockade of the development of visceral adiposity, reduced serum and liver cholesterol levels, the normalization of glucose intolerance and insulin resistance, and an anti-proliferative effect. The peptides of the invention, such as (arg0) n-Ang-(1-7), optionally can be associated with a carrier system or controlled drug release system.
摘要翻译：本发明涉及所述肽（为arg0）N血管紧张素 - （1-7）[（为arg0）正的Ang-（1-7）]，其中n为1至10（的Xaa - 天冬氨酸 - 精氨酸 - 缬氨酸 - 酪氨酸 -Ile-His的-PRO; SEQ ID NO：1其中Xaa darstellt 1〜10 L-精氨酸残基），所有这一切是通过在昂的）的氨基末端位置（1-7插入至少一个氨基酸精氨酸产生，如孔含有该肽和其用于治疗疾病或病症没有治疗或预防中使用的药物组合物是因或具有减少的一氧化氮的产生相关联。非限制性疾病或病症论文的例子心肺及肝脏疾病，血管疾病，代谢性疾病，神经性疾病，生殖泌尿道疾病，骨骼肌疾病，肾脏疾病，皮肤疾病，脱发或肿瘤。该肽能够使得，例如，主动脉和肠系膜血管的扩张，减少平均动脉血压的，体重增加的减少，内脏肥胖的发展的封锁，减少的血清和肝脏胆固醇水平，葡萄糖耐受不良的正常化和胰岛素抵抗，和抗增殖作用。发明，：如（为arg0）的肽正的Ang-（1-7），可以任选地与载体系统或控制药物释放系统相关联。

3. 发明公开

EP2356995A2 Process of preparation of formulations of the peptide Angiotensin-(1-7) and its analogues, agonists and antagonists using cyclodextrins, liposomes and biodegradable polymers and/or mixtures and products thereof 审中-公开
标题翻译：使用环糊精，脂质体和生物可降解聚合物和/或其混合物和产物制备肽血管紧张素 - （1-7）及其类似物，激动剂和拮抗剂制剂的方法
公开(公告)号：EP2356995A2
公开(公告)日：2011-08-17
申请号：EP11160834.5
申请日：2002-11-05
申请人： Universidade Federal de Minas Gerais-UFMG
发明人： Santos, Robson Augusto Souza , Nadu, Ana Paula , Frezard, Frederic Jean Georges , Sinisterra, Rubén Dario
IPC分类号： A61K38/08 , A61P9/00 , A61K9/127 , A61K9/16 , A61K47/40
CPC分类号： B82Y5/00 , A61K9/1271 , A61K9/1647 , A61K38/085 , A61K47/6951
摘要： There is no description in the state of technique of a formulation, application or product of D-Ala 7 -Angiotensin-(1-7) (A-779) and analogues and derivatives, D-Pro 7 -Angiotensin-(1-7) and analogues or derivatives or of Ang-(1-7) analogues or derivatives using cyclodextrines, liposomes, biodegradable polymers and its derivatives for the study or treatment of arterial hypertension and other cardiovascular diseases and its complications, wounds, burns, erithema, tumors, diabetes mellitus, sperm mobility, nephropathy, gastrointestinal and gynaecological disorders, angiogenesis, angioplatsy, alopecia and blood diseases in animals of warm blood, or as ligands for de G-protein-coupled receptor MAS. This characterizes the present invention as a more effective option for the study and treatment of pathologies associated or not to this receptor. The present invention is characterized by the combination of two different technologies: the molecular encapsulation of the peptide Angiotensin-(1-7) and its analogues and derivates in cyclodextrin and the microencapsulation in biodegradable polymers and liposomes. It is also characterized by the increase of this peptide and its analogues and derivatives using the formulation of the present invention.
摘要翻译：在D-Ala7-血管紧张素 - （1-7）（A-779）及其类似物和衍生物，D-Pro7-血管紧张素 - （1-7）和其衍生物的制剂，应用或产品的技术状态中没有描述用于研究或治疗动脉高血压和其他心血管疾病及其并发症，伤口，烧伤，鼻炎，肿瘤，糖尿病的使用环糊精，脂质体，生物可降解聚合物及其衍生物的类似物或衍生物或Ang-（1-7）类似物或衍生物精子活动能力，肾病，胃肠和妇科疾病，血管生成，血管扩张症，脱发和血液疾病，或作为G蛋白偶联受体MAS的配体。这将本发明表征为研究和治疗与这种受体相关或不相关病理的更有效的选择。本发明的特征在于两种不同技术的组合：肽类血管紧张素 - （1-7）及其类似物和衍生物在环糊精中的分子包封以及生物可降解聚合物和脂质体中的微囊化。其特征还在于使用本发明的制剂增加了该肽及其类似物和衍生物。

4. 发明公开

EP2264048A2 PEPTIDE DES-[ASP1]-[ALA1],ANGIOTENSIN-(1-7) AGONIST AND PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF DISEASES 有权
标题翻译： PEPTIDE DES [ASP1] - [ALA1] - 血管紧张素 - （1-7）激动剂和药物化合物FOR疾病治疗
公开(公告)号：EP2264048A2
公开(公告)日：2010-12-22
申请号：EP09841273.7
申请日：2009-02-13
申请人： Universidade Federal De Minas Gerais - UFMG
发明人： SOUZA DOS SANTOS, Robson Augusto , FERREIRA, Anderson José , SINISTERRA, Ruben Dario
IPC分类号： C07K7/14
CPC分类号： A61K38/085 , C07K7/14
摘要： "PEPTIDE DES-[ASP 1 ]-[ALA 1 ] ANGIOTENSIN-(1-7) AGONIST AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES"
The present invention is related to the peptide Des-[Asp 1 ]-[Ala 1 ]-Angiotensin-(1-7) (Ala 1 -Arg 2 -Val 3 -Tyr 4 -Ile 5 -His 6 -Pro 7 ) and/or its related compounds as vasodilating and cardioprotective agents to be used in mammals. This invention also comprises the production of compositions containing Des-[Asp 1 ]-[Ala 1 ]-Angiotensin-(1-7) and/or its related compounds and its use in methods for treating and preventing diseases.
摘要翻译： “肽DES [ASP 1] - [ALA 1]血管紧张素 - （1-7）激动剂和药物组合物疾病治疗的” 本发明涉及肽Des- [ASP 1] - [丙氨酸1] - 血管紧张素 - （1-7）（丙氨酸1 -Arg 2 -Val 3 -Tyr 4 -Ile 5 -His 6 -Pro 7）和/或其相关化合物作为血管舒张和心脏保护剂在哺乳动物中使用。本发明因此包括生产含沙漠[ASP 1]组合物的 - [丙氨酸1] - 血管紧张素 - （1-7）和/或其相关化合物及其在方法中使用的用于治疗和预防疾病。

5. 发明公开

EP2247730A1 TOXIN OF THE SPIDER PHONEUTRIA NIGRIVENTER FOR TREATMENT OF ERECTILE DYSFUNCTION 审中-公开
标题翻译：毒素SPIDER Phoneutria nigriventer麻烦的动力的治疗
公开(公告)号：EP2247730A1
公开(公告)日：2010-11-10
申请号：EP09706043.8
申请日：2009-01-30
申请人： Universidade Federal de Minas Gerais-Ufmg , Fundação Ezequiel Dias - Funed , Fundação de Amparo à Pesquisa do Estado de Minas Gerais - Fapemig
发明人： PEREZ GARCIA, Maria elena de Lima , SINISTERRA MILLÁN, Rubén Dario , NUNES, Kênia Pedrosa , LEITE, Rômulo , LANZA, Luciana Franco , VASCONCELOS DINIZ, Marcelo Ribeiro , RICHARDSON, Michael , VALENTIM, Maria do Carmo , PIMENTA, Adriano Monteiro de Castro
IPC分类号： C12N15/12 , C07K14/435 , A61K38/17
CPC分类号： C07K14/43518 , A61K38/00
摘要： The present invention concerns a method for male erectile function potentiating by means of toxin Tx2-6 from the spider Phoneutria nigriventer.

6. 发明公开

EP2086558A2 PH 1B TOXIN, CDNA OF PH 1 B TOXIN GENE, PHARMACEUTICAL COMPOSITIONS CONTAINING PH 1B TOXIN, PROCESSES FOR THEIR OBTENTION AND PRODUCT 审中-公开
标题翻译： PH 1B毒素的cDNA PH 1乙毒素基因，含有PH 1B毒素的药物组合物，提取工艺及产品
公开(公告)号：EP2086558A2
公开(公告)日：2009-08-12
申请号：EP07815759.1
申请日：2007-11-21
申请人： Universidade Federal de Minas Gerais
发明人： GOMES, Marcus Vinicius , MÁXIMO PRADO, Marco Antônio , PRADO, Vânia Fátima
IPC分类号： A61K35/64 , A61P25/02 , A61P25/04 , A61P9/06 , A61P9/10
CPC分类号： C07K14/43518 , A61K38/00
摘要： Methods and compositions for blocking calcium channels with a spider toxin Phoneutria nigriventer are provided. For easy identification the toxin will be sometimes generally referred to as Phα-1B during the present description of the invention. The toxin comprises a 55-amino acid toxin having a molecular weight of approximately 6,017. This Phα-1B spider toxin was found to block calcium channels within the nervous system. The synthetic gene responsible for producing this toxin has been designed and cloned. This gene and/or its derivative provide a mechanism by which the toxin can be produced using recombinant DNA expression technologies. The present invention further relates to methods of treating neurological diseases and pain by applying the isolated and identified toxins. The toxin Phα-1B may provide beneficial effects on pain and certain neurological conditions including seizures, ischemic- hypoxic, CNS damage, and neurodegenerative disorders. It was also found that the toxins are effective as tags in probing calcium channels.

7. 发明公开

EP2018185A1 USE OF MAS-G-PROTEIN-COUPLED RECEPTOR AGONISTS IN THE TREATMENT OF THE METABOLIC SYNDROME, ITS COMPONENTS AND ITS COMPLICATIONS 有权转让
标题翻译： MAS的G蛋白偶联受体的激动剂的代谢综合征，及其组成和并发症的治疗用途
公开(公告)号：EP2018185A1
公开(公告)日：2009-01-28
申请号：EP07719268.0
申请日：2007-04-26
申请人： Universidade Federal De Minas Gerais , Max-Delbrück-Centrum für Molekulare Medizin (MDC)
发明人： SOUZA DOS SANTOS, Robson Augusto , SOUSA SANTOS, Sergio Henrique , ALVAREZ LEITE, Jaqueline Isaura , MATOS DE MOURA, Marina , SIQUEIRA HAIBARA, Andrea , RODRIQUES FERNANDEZ, Luciana , BADER, Michael , ALENINA, Natalia , SINISTERRA, Rubens Dario
IPC分类号： A61K45/00 , A61K38/08 , A61K31/415 , A61P3/00 , G01N33/50
CPC分类号： A61K31/415 , A61K38/085 , G01N33/68 , G01N33/6893 , G01N2333/726 , G01N2500/00
摘要： The present invention is characterized by the use of Mas-G- protein-coupled receptor agonists for the control, prevention and treatment of the body levels of triglycerides, cholesterol and glucose, as well as of hyper- tension and possible increase in body weight, which are characteristic of the clinical manifestation of the metabolic syndrome and its complications. Another characteristic of the invention is the use of Mas-G-protein- coupled receptor agonists, including the Angiotensin-(1-7) peptide and its analogs, agonists, either peptidic or non-peptidic, as modulators of the mani- festations of insulin resistance and glucose intolerance and in the prevention and treatment of the related alterations. The invention claims the use of MAS-G-protein-coupled receptor agonists, formulated with pharmaceutically and pharmacologically acceptable excipients or carriers, and Mas-G-protein-coupled receptor agonists, includ- ing the Angiotensin-(1-7) peptide and its analogs, agonists, either peptidic or non-peptidic, as modulators of the metabolic syndrome, the diseases that compose it and its complications.

8. 发明公开

EP1904087A2 USE OF MAS G-PROTEIN-COUPLED RECEPTOR AGONISTS AND ANTAGONISTS AS APOPTOTIC ACTIVITY MODULATORS FOR PREVENTION AND TREATMENT OF DISEASES 审中-公开
标题翻译： USE MAS G蛋白偶联型受体的激动剂和拮抗剂作为用于预防和治疗疾病的细胞凋亡活性的调节剂的
公开(公告)号：EP1904087A2
公开(公告)日：2008-04-02
申请号：EP06741348.4
申请日：2006-06-28
申请人： Universidade Federal de Minas Gerais
发明人： SOUZA DOS SANTOS, Robson Augusto , VELOSO BRANT PINHEIRO, Sérgio , DE FARIA E SILVA, Raphael , SILVA LULA, Ivana , BARROS DE SOUSA, Frederico , FRÉZARD, Frédéric Jean Georges , DOS REIS, Adelina Martha , DE FRANCA, Luiz Renato , FERREIRA, Anderson, José , SINISTERRA, Rubén Dario , CAMPAGNOLE-SANTOS, Maria José , DE OLIVEIRA SAMPAIO, Walkyria Neyde , DE CASTRO LEAL, Marcelo , KAPPES BECKER, Lenice
IPC分类号： A61K38/08 , A61P43/00
CPC分类号： A61K38/085
摘要： The present invention is characterized by the use of Mas G- protein-coupled receptor agonists and antagonists as apoptotic activity modulators for study, prevention and treatment of diseases. It is further characterized by the use of Mas G-protein-coupled receptor agonist and antagonists for modulation of the apoptotic activity involving alterations in the activity of the protein kinase B/Akt. Another characteristic of the invention is the use of Mas G-protein-coupled receptor agonists and antagonists, including the Ang- (1-7) peptide and its analogues, agonists and antagonists, either peptidic or non-peptidic, as modulators of apoptotic activity for study, prevention and treatment of degenerative diseases of organs and systems, as an auxiliary measure for organs transplantation, treatment with embryonic, non- embryonic stem cells, re-implantation of organs and tissues and other treatments that need temporary or chronic reduction of the apoptotic activity, not limitative. The invention further claims the use of Mas G-protein-coupled receptor agonists and antagonists, including the Angiotensin-(1-7) peptide and its analogues, agonists and antagonists, either peptidic or non-peptidic, formulated with pharmaceutically and pharmacologically acceptable excipients or carriers, as modulators of the apoptotic activity.

9. 发明公开

EP1877049A2 INCLUSION COMPOUNDS OF DIOCLEIN, FLORANOL OR ANALOGS WITH CYCLODEXTRIN AND THEIR USE FOR TREATING CARDIOVASCULAR DISEASES 审中-公开
标题翻译：作者DIOCLEIN，FLORANOL或其类似物与环糊精，其应用心脏病周期的治疗包合物
公开(公告)号：EP1877049A2
公开(公告)日：2008-01-16
申请号：EP06721619.2
申请日：2006-03-30
申请人： Universidade Federal de Minas Gerais
发明人： SOARES LEMOS, Virginia , DE FRANÇA CORTES, Stayner , ALMEIDA RESENDE, Bruno , LINS GONÇALVES, Roberta , SINISTERRA MILAN, Ruben Darío , SCHMITT, Martine , LUGNIER, Claire , BOURGUIGNON, Jean-Jacques
IPC分类号： A61K31/352
CPC分类号： A61K9/1647 , A61K31/352 , A61K47/6951 , B82Y5/00
摘要： The present invention relates to dioclein, floranol or natural or synthetic analogs; associated to inclusion compounds with the cyclodextrins and to controlled-release devices using biodegradable or non-biodegradable polymer, such as PLGA, PLA, PGA or mixtures thereof; their respective pharmaceutical compositions for the study and treatment of cardiovascular diseases and associated products. The substances developed in the present invention have been tested for their ability of inhibiting different isoforms of PDE' s. These are also the first substances, and their pharmaceutical compositions, in the therapeutical arsenal, capable of inhibiting, in a potent and selective manner, the isoform of type-1 (PDEl) phosphodiesterase. The present invention used two flavonoids as forms that inhibits phosphodiesterases of types 1 to 5: dioclein and floranol, as well as their analogs and pharmaceutical compositions, using the cyclodextrins and their inclusion compounds, as well as pharmaceutical and pharmacologically acceptable excipients.

10. 发明授权

EP0963437B1 THE PROCESS FOR THE EXPRESSION AND PRODUCTION OF THE RECOMBINANT HUMAN BETA-CIS INTERFERON 失效
标题翻译：方法表达和重组生产，人力BETA-CIS干扰素
公开(公告)号：EP0963437B1
公开(公告)日：2005-10-26
申请号：EP97953597.8
申请日：1997-12-19
申请人： Universidade Federal De Minas Gerais
发明人： PEREGRINO FERREIRA, Paulo Cesar , GEESSIEN KROON, Erna , GOLGHER, Romain, Rolland , BONJARDIM, Cláudio, Antonio , DE CARVALHO, Alex, Fiorini
IPC分类号： C12N15/22
CPC分类号： C07K14/565 , A61K38/00 , Y02A50/473
摘要： The invention provides a new human interferon (IFN)-beta variant cloned from an amniotic cell library, a cDNA encoding it, and processes for its production and purification. The variant, termed interferon beta-cis, differs from previously known hIFN-beta isoforms by the substitution of a Cys residue for the Tyr present at position 60. Recombinant IFN beta-cis exhibits antiviral activity characteristic of IFN-beta.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式